Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LIB 003

Drug Profile

LIB 003

Alternative Names: LIB-003

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LIB Therapeutics
  • Class Antihyperlipidaemics; Recombinant fusion proteins
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 16 Nov 2019 Efficacy and safety data from a phase IIb trial in Hypercholesterolaemia presented at the American Heart Association Scientific Sessions 2019 (AHA-2019)
  • 11 Nov 2019 LIB Therapeutics completes enrolment in its phase II trial for Hypercholesterolaemia (Adjunctive therapy) in USA (NCT03847974)
  • 07 Nov 2019 Phase-III clinical trials in Hypercholesterolaemia (Adjunctive treatment) in South Africa, USA (SC) (NCT04034485)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top